Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. We show 1 historical shares outstanding datapoints in our GPCR shares outstanding history coverage, used to compute GPCR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GPCR market cap history over the course of time is important for investors
interested in comparing GPCR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GPCR versus a peer is one thing; comparing
GPCR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GPCR can fluctuate over the course of history.
With this page we aim to empower investors researching GPCR by allowing them to research the GPCR market cap history. |
Free GPCR Email Alerts:
Video: The Importance of Market Cap
